Compugen Ltd. Overview
Pro stress-test →Compugen Ltd is a clinical-stage cancer immunotherapy company. The company is focused on therapeutic discovery and development, utilizing its AI/ML-powered computational discovery capabilities to identify novel drug targets and biological pathways.
Strategic Profile
Pro stress-test →With a market capitalization of approximately $197.94 million, Compugen is actively working on several clinical-stage programs, including COM701, which targets immune checkpoints discovered through computational methods. The company has a solid financial position with a cash runway expected to last into 2029, supported by a non-dilutive transaction in December 2025 providing $65 million upfront and a potential $25 million milestone payment from AstraZeneca royalties.
Competitive Landscape
Pro stress-test →Compugen competes in immuno-oncology with partnerships including Bristol-Myers Squibb on COM701 combinations and AstraZeneca for bi-specific antibody development. The company differentiates through its computational AI/ML platform for target discovery rather than traditional screening approaches, competing with larger pharma and specialized biotech in oncology immunotherapy.
Industry Context
Compugen Ltd. operates in Biotechnology - Oncology Immunotherapy.
Key facts
Founded: 1993 · Headquarters: Holon, Israel · Revenue: $2.18M (Q1 2026) · Market cap: $197.94M